Balyasny Asset Management
CRNX icon

Balyasny Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Balyasny Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-233,197
Closed -$10.9M – 2979
2025
Q4 		$10.9M Buy
233,197
+219,152
+1,560% +$9.76M 0.01% 981
2025
Q3 		$585K Buy
+14,045
New +$449K ﹤0.01% 2328
2024
Q4 		– Sell
-53,042
Closed -$2.71M – 2825
2024
Q3 		$2.71M Sell
53,042
-61,595
-54% -$3.18M ﹤0.01% 1553
2024
Q2 		$5.13M Buy
+114,637
New +$5.29M 0.01% 1159
2023
Q3 		– Sell
-29,089
Closed -$524K – 2324
2023
Q2 		$524K Buy
+29,089
New +$580K ﹤0.01% 1843
2023
Q1 		– Sell
-744
Closed -$13.6K – 2728
2022
Q4 		$13.6K Buy
+744
New +$13.1K ﹤0.01% 2527

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Balyasny Asset Management's CRNX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 233,197 shares — an estimated $10.9M sold.

Balyasny Asset Management first reported a position in CRNX in Q4 2022 and held it in 6 quarters. The position peaked at $10.9M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 233,197 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $10.9M.
  • Balyasny Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Balyasny Asset Management's Crinetics Pharmaceuticals position peaked at $10.9M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.